Asset
Bexobrutideg
Nurix Therapeutics Inc. Common stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06717269 | phase1 | completed | 2024-11-30 | 2026-05-01 | Nurix Therapeutics, Inc. | A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers |
| NCT07221500 | phase2 | recruiting | 2025-10-15 | 2028-01-01 | Nurix Therapeutics, Inc. | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) |
| NCT05131022 | phase1 | recruiting | 2022-04-13 | 2027-01-01 | Nurix Therapeutics, Inc. | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies |
| NCT06691828 | phase1 | completed | 2024-11-01 | 2024-11-28 | Nurix Therapeutics, Inc. | Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 |
| NCT07516093 | phase3 | recruiting | 2026-08-03 | 2029-10-01 | Nurix Therapeutics, Inc. | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL |
FDA applications (0)
This company has no applications containing this asset.